Cytosorbents (NASDAQ:CTSO) Earns “Neutral” Rating from HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $1.00 target price on the medical research company’s stock. HC Wainwright’s price target points to a potential upside of 3.09% from the stock’s previous close. HC Wainwright also issued estimates for Cytosorbents’ FY2028 earnings at ($0.07) EPS and FY2029 earnings at ($0.05) EPS.

Several other equities analysts have also issued reports on the company. StockNews.com started coverage on Cytosorbents in a research report on Thursday. They set a “hold” rating for the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Cytosorbents has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Cytosorbents stock opened at $0.97 on Thursday. The stock has a market cap of $53.04 million, a price-to-earnings ratio of -2.69 and a beta of 0.78. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.04.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. As a group, research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors have recently modified their holdings of the business. Avenir Corp lifted its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after buying an additional 118,387 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the fourth quarter worth $99,000. Millennium Management LLC bought a new stake in Cytosorbents in the 4th quarter valued at $30,000. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.